Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
@article{ACTR9137,
author = {Panagiota Economopoulou and Ioannis Kotsantis and Amanda Psyrri},
title = {Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?},
journal = {AME Clinical Trials Review},
volume = {2},
number = {0},
year = {2024},
keywords = {},
abstract = {},
issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/9137}
}